Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Operating Leases (2019 - 2024)

Historic Operating Leases for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Q4 2024 value amounting to $2.0 million.

  • Syndax Pharmaceuticals' Operating Leases rose 25449.83% to $2.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.0 million, marking a year-over-year increase of 25449.83%. This contributed to the annual value of $2.0 million for FY2024, which is 25449.83% up from last year.
  • According to the latest figures from Q4 2024, Syndax Pharmaceuticals' Operating Leases is $2.0 million, which was up 25449.83% from $133000.0 recorded in Q2 2024.
  • Over the past 5 years, Syndax Pharmaceuticals' Operating Leases peaked at $2.0 million during Q4 2024, and registered a low of $22000.0 during Q2 2021.
  • For the 5-year period, Syndax Pharmaceuticals' Operating Leases averaged around $565315.8, with its median value being $578000.0 (2023).
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 9083.33% in 2021, then surged by 249090.91% in 2022.
  • Over the past 5 years, Syndax Pharmaceuticals' Operating Leases (Quarter) stood at $101000.0 in 2020, then skyrocketed by 603.96% to $711000.0 in 2021, then decreased by 0.28% to $709000.0 in 2022, then decreased by 18.48% to $578000.0 in 2023, then surged by 254.5% to $2.0 million in 2024.
  • Its last three reported values are $2.0 million in Q4 2024, $133000.0 for Q2 2024, and $327000.0 during Q1 2024.